This is so amazing, I think it deserves it’s own topic! Thanks for posting it!!!
Didn’t know where to post this. But there is a section about Metformin - talk by Dr. Nir Barzilai starting at 1:33:09.
Professor James Kirkland’s, on senolytics, starts at 42:20.
The first speaker, Professor Thomas Rando 16:30 talks about Stem Cells and Ageing.
I. Executive Summary
The afternoon session of the Longevity Science Singapore Conference outlines a paradigm shift from reactive, dichotomous “sick care” to proactive, evidence-based longevity medicine. Dr. Andrea Maier introduces a multi-organ aging framework validated by plasma proteomics network analysis within the UK Biobank dataset. This tracking reveals a predictable, sequential decline cascade across a 12-year timeline: primary pulmonary degradation actively accelerates subsequent cardiac dysfunction, which cascades into muscle deterioration, hepatic impairment, and ultimate renal failure. Halting this multi-system slide requires early, deep phenotyping combined with multi-omic profiling and targeted biological interventions.
Dr. Thomas Rando evaluates the intrinsic and extrinsic regulators of muscle stem cell (MuSC) dynamics. While exercise—specifically voluntary wheel running—rejuvenates aged MuSCs by upregulating Cyclin D1 and suppressing anti-regenerative TGF-beta/Smad3 signaling cascades, nutrient deprivation introduces a distinct evolutionary trade-off. Short-term fasting, ketogenic diets, and exogenous beta-hydroxybutyrate (BHB) push MuSCs into a state of “deep quiescence.” Mechanistically acting as a non-metabolic signaling molecule, BHB functions as an endogenous histone deacetylase (HDAC) inhibitor, driving the hyperacetylation and transcriptional activation of p53. This deep quiescent state transiently delays immediate muscular regeneration post-injury due to sluggish cell-cycle re-entry; however, it confers exceptional resilience against oxidative, chemical, and genotoxic stresses, systematically preventing age-associated mitotic catastrophe.
Dr. James Kirkland addresses the heterogeneity of cellular senescence and the systemic spread of the senescence-associated secretory phenotype (SASP). Up to 70% of senescent cells leverage senescent cell anti-apoptotic pathways (SCAPs) to survive the pro-apoptotic factors they secrete. These cells exert an endocrine threshold effect; transplanting minor numbers of senescent cells drives global frailty and all-cause mortality in murine models, a process mediated by cell-free mitochondrial DNA activating host dendritic cells. Intermittent, “hit-and-run” senolytic dosing using combinations like Dasatinib and Quercetin (DQ) or isolated Fisetin exploits brief elimination half-lives to ablate pro-apoptotic senescent pools while sparing beneficial cells essential for tissue remodeling. Early open-label human pilot data in idiopathic pulmonary fibrosis patients demonstrates notable functional improvements in gait speed and physical parameters alongside elevations in urinary alpha-klotho, though Kirkland notes a high projected phase 2 clinical trial failure rate (~80%).
Finally, Dr. Nir Barzilai details the targeting of aging hallmarks using Metformin via the upcoming Targeting Aging with Metformin (TAME) multi-center clinical trial framework. Retrospective clinical registry data indicates that metformin-treated diabetics achieve a significant survival advantage over matched non-diabetic controls. However, geroscience therapeutics present critical biochemical trade-offs. Metformin-induced reductions in circulating insulin-like growth factor 1 (IGF-1) and free testosterone represent age-dependent liabilities, indicating that prophylactic deployment in youthful cohorts could compromise baseline physiological fitness and somatic development. Genetic analysis of exceptional longevity cohorts reveals targetable, protective variants in APOC3 and CETP that insulate centenarians against severe risk alleles like APOE4, highlighting a blueprint for downstream pharmaceutical design.
II. Insight Bullets
- Dichotomous Modern Medicine Limitations: Standard clinical models rely on arbitrary cutoffs to diagnose disease (e.g., COPD, heart failure) after substantial organ function decline has occurred, rather than optimizing organ function during subclinical degeneration.
- Sequential Multi-Organ Decline Cascade: Long-term proteomic tracking from the UK Biobank establishes that organ degradation operates in a predictable timeline: primary pulmonary decline precipitates cardiac failure, which sequentially compromises muscle mass, hepatic health, and renal clearance.
- Organ-Specific Proteomic Estimation: Modern elastic net regularization and machine learning models applied to plasma proteomics allow the construction of distinct, organ-resolved biological clocks capable of predicting longitudinal all-cause mortality and specific disease onset.
- Causal Directionality in Aging Clocks: Cross-cohort validation across American, British, and Chinese populations confirms that organ-specific biological acceleration represents a causal vector for chronic pathology rather than a passive byproduct of chronological age.
- Heterochronic Parabiosis and Stem Cell Rejuvenation: Connecting the circulatory systems of young and old mice demonstrates that the systemic microenvironment dictates cellular age, with young blood restoring youthful regenerative capacity to aged muscle and liver stem cells.
- Sarcopenic Tissue Autonomy: Age-related muscle wasting (sarcopenia) is largely driven by muscle fiber-intrinsic mechanisms rather than a depletion or defect in the resting muscle stem cell niche, as muscle stem cells act primarily as a reserve pool for acute injury repair rather than daily homeostatic maintenance.
- Exercise-Induced Satellite Cell Priming: Three weeks of voluntary wheel running in senescent murine models completely rejuvenates muscle stem cell regenerative capacity, restoring structural tissue architecture post-injury to a youthful standard.
- Cyclin D1 and TGF-Beta Counter-Regulation: Mechanistically, physical exercise upregulates Cyclin D1 expression within muscle stem cells, which directly suppresses the anti-regenerative, pro-fibrotic TGF-beta/Smad3 signaling pathway that typically drives senescent tissue scarring.
- Nutrient Deprivation and the Deep Quiescence Trade-Off: Short-term fasting or strict ketogenic diets drive adult stem cells into an exaggerated state of “deep quiescence” characterized by cell shrinking, down-regulated mitochondrial content, and depressed baseline RNA levels.
- Delayed Regeneration Kinetics: While adult stem cells locked in deep quiescence are highly insulated from environmental insults, they exhibit delayed cell-cycle re-entry, which transiently delays immediate tissue healing and macromolecular reconstruction following acute physical trauma.
- Non-Metabolic Signaling Efficacy of Beta-Hydroxybutyrate: The induction of deep stem cell quiescence during ketosis is independent of energy metabolism or caloric consumption; direct exogenous administration of beta-hydroxybutyrate (BHB) completely replicates the cellular effects of a prolonged fast.
- BHB as an Endogenous HDAC Inhibitor: Within the adult stem cell niche, BHB operates as a direct inhibitor of histone deacetylases (HDACs), specifically upregulating the hyperacetylation and transcriptional activation of the tumor suppressor protein p53.
- Mitigation of Mitotic Catastrophe: Aged stem cells frequently undergo apoptotic death via mitotic catastrophe when forced to divide in the presence of accumulated DNA damage; hyperacetylation of p53 via ketone body signaling effectively prevents this structural failure.
- Requirement for Continuous Ketogenic Exposure: The protective, stress-resilient phenotypes induced by BHB are highly transient and decay rapidly upon nutrient reintroduction or ketone clearance, necessitating continuous or precisely cycled administration to maintain deep quiescence.
- Senescent Cell Heterogeneity: Between 30% and 70% of senescent cells express a destructive, pro-inflammatory and pro-apoptotic Senescence-Associated Secretory Phenotype (SASP), while the remaining fraction serves localized, non-apoptotic roles essential for baseline wound remodeling.
- Non-Peptide SASP Drivers: Bioactive lipids (including ceramides and prostanoids) and non-coding nucleotides (such as circular DNA, microRNAs, and cell-free mitochondrial DNA) are more potent systemic drivers of chronic inflammation than standard SASP peptide cytokines.
- The Senescence Endocrine Threshold Effect: Cellular senescence propagates systematically via an endocrine mechanism; transplanting a minor ratio of autologous, irradiated senescent fibroblasts into the peritoneum of a healthy mouse triggers systemic senescence in remote limbs and induces early all-cause mortality.
- Mitochondrial DNA and Organ Rejection: Cell-free mitochondrial DNA extruded by senescent cells in organs from donors over the age of 50 migrates to recipient regional lymph nodes, activating dendritic cells and driving accelerated acute transplant rejection.
- SCAP Network Survival Nodes: Senescent cells avoid self-destruction from their own pro-apoptotic SASP secretions by upregulating redundant Senescent Cell Anti-Apoptotic Pathways (SCAPs) that mimic the survival networks utilized by chronic lymphocytic leukemia cells.
- Hit-and-Run Senolytic Dosing Framework: Because senescent cells require weeks to reform but activate irreversible apoptotic cascades within two hours of targeted drug exposure, senolytic protocols utilize intermittent “hit-and-run” cycles to minimize systemic toxicity.
- Pharmacokinetic Half-Life Independence: Effective senolytic clearance depends on high peak serum concentrations rather than prolonged systemic exposure, matching the short elimination half-lives of compounds like Fisetin (3 hours in humans) and Dasatinib (3 hours in humans).
- Functional Regeneration via SCAP Ablation: Open-label human clinical trial data using combination Dasatinib and Quercetin (DQ) in idiopathic pulmonary fibrosis patients demonstrates clinically significant gains in physical function, including 6-minute walk distance and gait speed, without altering immediate baseline lung mechanics.
- Urinary Alpha-Klotho as a Senolytic Metric: Successful targeted clearance of senescent cell burdens within human cohorts triggers a corresponding upregulation of the protective, longevity-associated protein alpha-klotho within the urine.
- The Biomarker Core Ratio Requirement: Because single senescent biomarkers (e.g., SA-beta-galactosidase) capture only a fraction of the senescent pool, human clinical trials mandate composite profiling across at least 150 independent parameters including circulating SASP factors, p16 expression, and transcriptomic matrices.
- Metformin Monotherapy Survival Deviance: Epidemiological data from large-scale health registries reveals that patients with type 2 diabetes treated with first-line metformin exhibit a statistically significant survival advantage over matched, non-diabetic healthy controls.
- Hallmark-Wide Interventional Convergence: True geroprotective compounds—such as metformin or rapamycin—do not operate on isolated molecular targets; they systematically modulate all primary hallmarks of aging simultaneously by reverting old somatic cells to a more youthful state.
- The Composite Multi-Morbidity Endpoint Paradigm: The FDA-approved TAME trial framework shifts the clinical trial paradigm by ignoring single-disease endpoints, establishing a combined metric tracking the delayed onset of any major chronic disease (cancer, cardiovascular failure, cognitive decline, or mortality).
- Endocrine Liabilities of Metformin: Metformin deployment presents clear physiological trade-offs, notably reducing circulating free testosterone in aging males and suppressing serum insulin-like growth factor 1 (IGF-1) levels.
- Age-Dependent Growth Factor Utility: While the down-regulation of IGF-1 and growth factor signaling is highly protective against all-cause mortality and malignant transformation in geriatric populations, the same suppression in youthful cohorts represents a clear physiological liability that damages baseline fitness.
- Centenarian Genetic Architecture: Genomic dissection of exceptional longevity cohorts reveals that centenarians carry a standard load of chronic disease risk alleles (e.g., APOE4), but survive due to protective, innate modifiers like loss-of-function variants in APOC3 and targetable loci in CETP that structurally blunt age-associated risks.
IV. Actionable Protocol (Prioritized)
High Confidence Tier
Protocols backed by Level A/B evidence.
- Targeted Exercise-Induced Stem Cell Priming:
- Protocol: Engage in consistent aerobic and resistance training (mimicking the 3-week murine wheel-running model of Rando). This intervention must be prioritized to upregulate internal Cyclin D1 expression and systematically suppress pro-fibrotic TGF-beta/Smad3 signaling within the musculoskeletal niche.
- Evidence: Level A multi-cohort meta-analytic data involving over one million human subjects confirms that objectively measured physical activity step counts and structured exercise exert an absolute, non-linear reduction in all-cause mortality and functional frailty cascades [Maier et al., 2022].
- Clinical Metformin Deployment for Multi-Morbidity Delay (Aged Cohorts):
- Protocol: Utilize Metformin at standardized clinical doses (e.g., 1,500–2,000 mg daily) under strict medical supervision, tracking glycemic indices, renal clearance, and systemic inflammatory markers.
- Evidence: Level B retrospective cohort data spanning 78,241 subjects demonstrates that first-line metformin monotherapy significantly extends survival times, reducing all-cause mortality below that of matched non-diabetic controls [Bannister et al., 2014]. This paradigm forms the operational basis for the FDA-regulated TAME trial framework.
